The Securities and Exchange Board of India (Sebi) has granted a one-time extension for observation letters of public issue companies, valid until September 30, 2026. This move aims to ease fundraising pressures amid geopolitical tensions and market volatility, allowing companies to avoid regulatory duplication and recalibrate issuance plans.Read More
Foreign investors have sold Indian bonds worth over ₹8,000 crore. This follows Reserve Bank of India curbs on speculative rupee trading. These actions have significantly increased hedging costs for investors. Consequently, Indian bond yields have also risen. The selling pressure has been substantial, with daily outflows accelerating after the RBI’s measures were implemented.Read More
U.S. stocks ended mixed as investors tracked last-minute diplomatic efforts ahead of the Iran deadline to reopen the Strait of Hormuz. Rising oil prices and inflation concerns weighed on sentiment, while healthcare stocks gained on policy support. Markets remained cautious amid geopolitical uncertainty and mixed economic signals.Read More
Soleno Therapeutics has withdrawn its European drug application. This decision stems from its acquirer, Neurocrine Biosciences, prioritizing the United States market. The drug, Vykat XR, treats a rare genetic disorder. Neurocrine’s CEO confirmed the focus remains on the U.S. launch. This move aligns with a trend of delayed European launches amid U.S. pricing policy shifts.Read More
U.S. health insurer stocks surged after the government announced higher-than-expected Medicare Advantage payment rates for 2027, unlocking over $13 billion in additional payouts. The move eased concerns after weak earlier proposals, with analysts expecting improved margins and renewed investor confidence across the sector amid rising medical costs.Read More
Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.
